Linsitinib (OSI-906)

Name: Linsitinib (OSI-906)
Brand: Selleck Chemicals
SKU: S1091
Rating: 5 (145 reviews)

For research use only.

Catalog No.S1091

145 publications

CAS No. 867160-71-2

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Selleck's Linsitinib (OSI-906) has been cited by 145 publications

Cell Metab, 2021, S1550-4131(21)00326-0

PubMed: 34348115 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7719):499-503

PubMed: 30051890 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nature, 2016, 24;539(7630):570-574.

PubMed: 27820945 ( click the link to review the publication )

Cancer Cell, 2015,

PubMed: 25670080 ( click the link to review the publication )

Nat Med, 2014, 20(9):1027-34

PubMed: 25173427 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):564

PubMed: 34075028 ( click the link to review the publication )

Biochem J, 2021, 478(11):2059-2079

PubMed: 34002209 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01028-8

PubMed: 33403501 ( click the link to review the publication )

Cell Signal, 2021, 80:109911

PubMed: 33422645 ( click the link to review the publication )

Transl Oncol, 2021, 14(10):101181

PubMed: 34298440 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)621

PubMed: 33557316 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Theranostics, 2020, 10(26):12204-12222

PubMed: 33204338 ( click the link to review the publication )

Cell Rep, 2020, 33(3):108293

PubMed: 33086062 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )
Cancers (Basel), 2020, 12(12)E3717

PubMed: 33322337 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

FASEB J, 2020, 34(4):5363-5388

PubMed: 32067272 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(3):920-926

PubMed: 31871269 ( click the link to review the publication )

Mol Neurobiol, 2020, 57(3):1570-1593

PubMed: 31797328 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2020, 16;11:219

PubMed: 32373071 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 44(4):1649-1661

PubMed: 32945502 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 534:1-7

PubMed: 33302159 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biol Pharm Bull, 2020, 10.1248/bpb.b20-00362

PubMed: 32863294 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(1):186-194

PubMed: 31993315 ( click the link to review the publication )

Nat Commun, 2019, 10(1):518

PubMed: 30705270 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2244-2256

PubMed: 30833419 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Aging Cell, 2019, 18(3):e12932

PubMed: 30884121 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32668

PubMed: 31490549 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Cell Mol Life Sci, 2019, 76(6):1185-1199

PubMed: 30623207 ( click the link to review the publication )

Cancer Lett, 2019, 456:59-68

PubMed: 31042587 ( click the link to review the publication )
Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

FASEB J, 2019, 33(10):11210-11222

PubMed: 31291762 ( click the link to review the publication )

Cells, 2019, 8(4)

PubMed: 30965609 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2019, 74(9):1375-1385

PubMed: 30329021 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480400 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:5497467

PubMed: 31467485 ( click the link to review the publication )

J Agric Food Chem, 2019, 67(34):9510-9521

PubMed: 31382738 ( click the link to review the publication )

Biochimie, 2019, 163:108-116

PubMed: 31185266 ( click the link to review the publication )

Mol Med Rep, 2019, 19(4):2825-2830

PubMed: 30720075 ( click the link to review the publication )

Exp Ther Med, 2019, 17(3):1663-1669

PubMed: 30867686 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1777

PubMed: 29725014 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2546

PubMed: 29959327 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1580

PubMed: 30274984 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-1574

PubMed: 30279230 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0372

PubMed: 30397176 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4282-4296

PubMed: 29716918 ( click the link to review the publication )

Genes Dev, 2018, 32(13-14):915-928

PubMed: 29945888 ( click the link to review the publication )

Biomaterials, 2018, 155:64-79

PubMed: 29169039 ( click the link to review the publication )

Cancer Res, 2018, 78(14):3995-4006

PubMed: 29669759 ( click the link to review the publication )

Mol Cancer, 2018,

PubMed: 29455661 ( click the link to review the publication )
Cancers (Basel), 2018, 10(9)

PubMed: 30227608 ( click the link to review the publication )

J Mol Cell Biol, 2018, 10(4):331-340

PubMed: 29190376 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Cell Oncol, 2018, 41(3):283-296

PubMed: 29470830 ( click the link to review the publication )

Endocrinology, 2018, 159(1):285-296

PubMed: 29029116 ( click the link to review the publication )

Front Endocrinol, 2018, 9:178

PubMed: 29731738 ( click the link to review the publication )

Cell Signal, 2018, 52:12-22

PubMed: 30138697 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncotarget, 2018, 9(10):8810-8822

PubMed: 29507656 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(11):2795-2805

PubMed: 27903677 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1842-1853

PubMed: 28209619 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4014-4025

PubMed: 28619711 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28534511 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(4):328-340

PubMed: 27987211 ( click the link to review the publication )

Diabetologia, 2017, 60(8):1442-1453

PubMed: 28526921 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):705-716

PubMed: 28138037 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):88-101

PubMed: 28062706 ( click the link to review the publication )

Mol Cancer Res, 2017,

PubMed: 28289161 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2364

PubMed: 28539593 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4119

PubMed: 28646158 ( click the link to review the publication )

Endocrinology, 2017,

PubMed: 29028997 ( click the link to review the publication )
Cancer Biol Ther, 2017, 18(11):895-903

PubMed: 28696156 ( click the link to review the publication )

Cancer Med, 2017, 6(6):1353-1361

PubMed: 28440057 ( click the link to review the publication )

Biochimie, 2017, 138:62-69

PubMed: 28438671 ( click the link to review the publication )

J Cell Biochem, 2017, 118(7):1774-1781

PubMed: 27987331 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170083

PubMed: 28076448 ( click the link to review the publication )

Exp Lung Res, 2017, 43(1):29-37

PubMed: 28394654 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103465-103476

PubMed: 29262576 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28002807 ( click the link to review the publication )

Hepatology, 2017, 66(6):2002-2015

PubMed: 28653763 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27196766 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(6):481-93

PubMed: 27185872 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):411-22

PubMed: 26785999 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21485-21495

PubMed: 27535223 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 55(6):779-791

PubMed: 27438786 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Science, 2016, 352(6288):aad3018

PubMed: 27199435 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56826-56841

PubMed: 27472395 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27511-26

PubMed: 27050276 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(6):1373-82

PubMed: 25609059 ( click the link to review the publication )

Mol Cancer, 2015,

PubMed: 26041671 ( click the link to review the publication )

J Bone Miner Res, 2015, 30(11):1959-68

PubMed: 25990470 ( click the link to review the publication )
J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(3):1071-7

PubMed: 25485727 ( click the link to review the publication )

Mol Cancer Res, 2015,

PubMed: 26263910 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(17):2991-3004

PubMed: 26100015 ( click the link to review the publication )

Vascul Pharmacol, 2015, 10.1016/j.vph.2015.04.005

PubMed: 25921925 ( click the link to review the publication )

Med Oncol, 2015, 32(6):577

PubMed: 25956506 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116895

PubMed: 25603314 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26515601 ( click the link to review the publication )

Int J Clin Exp Med, 2015, 8(4):6563-7

PubMed: 26131286 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Neoplasia, 2014, 16(10):824-34

PubMed: 25379019 ( click the link to review the publication )

Endocrinology, 2014, 155(6):2102-11

PubMed: 24712877 ( click the link to review the publication )

Pharm Res, 2014, 31(11):3060-72

PubMed: 24906597 ( click the link to review the publication )

Arch Biochem Biophys, 2014, 558C:42-50

PubMed: 24933099 ( click the link to review the publication )

J Cell Biochem, 2014, 115(12):2208-17

PubMed: 25147082 ( click the link to review the publication )

Biometals, 2014, 27(2):317-32

PubMed: 24535192 ( click the link to review the publication )

Blood, 2013, 122(9):1621-33

PubMed: 23863897 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Diabetes, 2013, 62(10):3448-58

PubMed: 23801577 ( click the link to review the publication )

BMC Cancer, 2013, 13:245

PubMed: 23688189 ( click the link to review the publication )

Cancer Cell Biology, 2013, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Cancer Res, 2012, 73(2):834-43

PubMed: 23172312 ( click the link to review the publication )
Cancer Res, 2011, 71(21):6773-84

PubMed: 21908557 ( click the link to review the publication )

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Targets

IGF-1R ^[1] (Cell-free assay)	Insulin Receptor ^[1] (Cell-free assay)	IRR ^[1] (Cell-free assay)
35 nM	75 nM	75 nM

In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. ^[1]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
A4-Fuk	NWGxcVBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3T1XGlEPTB;MD6wNlgxPiEQvF2=	NH\qNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KS-1	NUGxVFN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXW4eItlUUN3ME2wMlA{QDN3IN88US=>	M2jse\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-11	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGq0cI9KSzVyPUCuNFc5OjJizszN	NIjzXYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
EW-1	NIG4U5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDGTWM2OD1yLkC4OVg2KM7:TR?=	NVHlUHN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HMV-II	NFHrUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnP3TWM2OD1yLkC4PFQ3KM7:TR?=	NIHieYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-205	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUnJR\|UxRTBwMUC0OVQh\|ryP	NEjGcJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ES1	NUL0SGR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFO5cFRKSzVyPUCuNVA3QTZizszN	NV;YTYt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GDM-1	NF;xUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYTJR\|UxRTBwMUO2O\|Ih\|ryP	NGH0[Yk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ML-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NI\kSlhKSzVyPUCuNVU5QTZizszN	NELVOXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Saos-2	NXzCSY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIn6c4FKSzVyPUCuNVY2OjZizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVnzcmdnUUN3ME2wMlE5OTN3IN88US=>	NEPrfZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
G-401	MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUTJR\|UxRTBwMUiyN{DPxE1?	MlfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-16	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{HlPWlEPTB;MD6xPFc4PyEQvF2=	M2\HfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EW-7	NVvPOmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIXIfmxKSzVyPUCuNVg5QDFizszN	NULzVmxmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H727	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnLkTWM2OD1yLkG5O\|k1KM7:TR?=	NHj5eWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV3IdoRWUUN3ME2wMlIxQTV3IN88US=>	NWDWUpgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H650	NW\ZeplIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHX0WHFKSzVyPUCuNlE{QDRizszN	NXr3TGI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2122	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYCxfG1MUUN3ME2wMlI{Ojl7IN88US=>	MnLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-N-DZ	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXHRXIRoUUN3ME2wMlI{Pjl6IN88US=>	NV3iNG1uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HT-29	NUXGcmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTBTWM2OD1yLkK0NlQ5KM7:TR?=	MoLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB771-HNC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkH1TWM2OD1yLkK1PVE2KM7:TR?=	MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HT-144	NIrafWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17VV2lEPTB;MD6yOlE6OSEQvF2=	M2O0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LAN-6	NVTPSZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3WycWlEPTB;MD6yOlM1QCEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
EW-18	MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIq2co1KSzVyPUCuNlcxODFizszN	NFPhe3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LS-1034	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYLJR\|UxRTBwMkexN\|Ih\|ryP	Mn3hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EW-11	M2TCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkXXTWM2OD1yLkK4OFMzKM7:TR?=	NHfT[WY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SNU-C1	NHzvXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDzTWM2OD1yLkK5N\|E{KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
RS4-11	M1zLNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk\0TWM2OD1yLkOzO\|U5KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES4	NVvufZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVLJR\|UxRTBwNEGwN\|gh\|ryP	NH7pVFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	M{\mXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\pPZFKSzVyPUCuOFE{PjhizszN	NH23bVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB10	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\XNpNtUUN3ME2wMlQ2PDN5IN88US=>	MmPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BFTC-905	M3ztcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4HmW2lEPTB;MD60Olc2QCEQvF2=	MoTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
A375	NVPtWGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{W0[mlEPTB;MD60O\|YyPyEQvF2=	MmTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SJRH30	NYLoV2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF[1[25KSzVyPUCuOVA5OjJizszN	NVLrbYtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NOS-1	NEHxNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVHJR\|UxRTBwNUKyOlch\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SIG-M5	MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFnLXmFKSzVyPUCuOVM2PTdizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DOK	M{C2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYTsSmpSUUN3ME2wMlU2PiEQvF2=	NX;kNINTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NB69	NVLSZ\|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF;TW5JKSzVyPUCuOVgzPTdizszN	Mme2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-NEP-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlHyTWM2OD1yLk[wNlM3KM7:TR?=	NYLNZ21iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-MM-2	M2rLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3nBPGlEPTB;MD62OVQ6OSEQvF2=	MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H358	M2KzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWfnRVliUUN3ME2wMlY4ODh{IN88US=>	NVPnfmp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RH-1	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XtWGlEPTB;MD63OFg2QSEQvF2=	NFXXd289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NH-12	NV7FU3VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWPiUoRYUUN3ME2wMlc3ODR4IN88US=>	MmT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TE-12	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUTJR\|UxRTBwN{[0PFYh\|ryP	NEO4OW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-668	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3fjSmlEPTB;MD64OFY3PiEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
PANC-08-13	M1TPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHT2N4VKSzVyPUCuPFY{PzdizszN	NEnScFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HCC2998	NE\HV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXfJR\|UxRTBwOEiyOlMh\|ryP	NXjGVHQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ABC-1	MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn:3TWM2OD1yLkmwN\|UzKM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ES6	NXzzcWdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3PWOGlEPTB;MD65NVA3PiEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SNU-387	MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVTJR\|UxRTBwOUmzPVMh\|ryP	NWXQRYpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CMK	NFrzWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYPBPVc1UUN3ME2wMlk6QTJ7IN88US=>	M1vYOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SJSA-1	NFrBb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFP6NFVKSzVyPUGuNFM3PTNizszN	NXTDUZJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SIMA	MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mm\vTWM2OD1zLkC2PFI2KM7:TR?=	NHjLS\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ES3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\LfGRKSzVyPUGuNVIzQTdizszN	MofqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
IGROV-1	M3\ENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIPNVWZKSzVyPUGuNVU1PDRizszN	NV3Bd5Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MEL-JUSO	NFfqbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmK5TWM2OD1zLkG1O\|U6KM7:TR?=	NGq5NJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
T84	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnUXVFKSzVyPUGuNlA6OTRizszN	NX;CVHdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CAL-85-1	M{TX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHnOOVJKSzVyPUGuNlMyOzhizszN	MmrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
RD	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFvFcGxKSzVyPUGuNlY1PTVizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TE-8	NIP2W3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{HDTGlEPTB;MT6zNVQ3OiEQvF2=	M1LjOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
L-363	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWnJR\|UxRTFwM{SyNFgh\|ryP	NYizfFNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EKVX	NFLJSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX7JR\|UxRTFwM{S1Olgh\|ryP	NGHNbmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-MEL-3	NIjX[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFzMeIVKSzVyPUGuOFg2PTZizszN	MmPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TGBC24TKB	MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGH1NWxKSzVyPUGuOVAyQTNizszN	M3HicFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H1770	NIjEc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHrybVhKSzVyPUGuOVEyOTNizszN	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HuH-7	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3PUdGlEPTB;MT62NFA6QCEQvF2=	NVnWPJV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HL-60	MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4HhXmlEPTB;MT62OlkzQCEQvF2=	M4PBTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-1	M4fsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkDFTWM2OD1zLkewPVQ2KM7:TR?=	M1fUTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LC-2-ad	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\MSGlEPTB;MT63N\|g5PyEQvF2=	NGTKcWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LB647-SCLC	NXn1S5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NITn[pFKSzVyPUGuO\|Y2QDNizszN	Ml7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H2171	NHjGbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVrJR\|UxRTFwN{e3NVYh\|ryP	NYnWe\|NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-PN-DW	NH;YdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml;iTWM2OD1zLkmxNlk5KM7:TR?=	M4naclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MC-IXC	NVTXe2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIi0Vo1KSzVyPUGuPVg6QCEQvF2=	MmLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LS-513	M2PrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYm0PHBuUUN3ME2yMlA2OzB3IN88US=>	M1;BTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EW-3	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWTJR\|UxRTJwMEm4OFQh\|ryP	MoCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
OPM-2	M4jHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUPjZpF{UUN3ME2yMlExOiEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LP-1	MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGPZVGVKSzVyPUKuNlU5ODdizszN	M4jBWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LU-134-A	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnLtTWM2OD1{LkK3O{DPxE1?	NFPUXnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CP66-MEL	MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWXRTZpXUUN3ME2yMlI6ODF2IN88US=>	NH3kOmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HCC1143	NXT0OI1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{XZOGlEPTB;Mj60OVM3QCEQvF2=	M1LOb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LOXIMVI	M1rsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUnJR\|UxRTJwNkCyNUDPxE1?	M{jq[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TE-10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NY[wTnp1UUN3ME2yMlcxQDN6IN88US=>	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1882	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVHJR\|UxRTJwN{WyNlch\|ryP	NYjBbY44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CHP-126	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVzqdpBbUUN3ME2yMlc3OzF5IN88US=>	NHnNR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1623	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYTJR\|UxRTJwOUKwNlQh\|ryP	NHXubII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
GB-1	M1Pqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnTjTWM2OD1{LkmzOFA1KM7:TR?=	NHzTSo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
RCC10RGB	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIXZWHBKSzVyPUKuPVUzQDFizszN	NELSO3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2141	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFTBPVRKSzVyPUKuPVY5QTZizszN	NUPhSZFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GI-ME-N	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnXtTWM2OD1\|LkCwOVY2KM7:TR?=	M1jPS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H526	MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2mzOWlEPTB;Mz6wOFA5PSEQvF2=	Ml;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H747	NWnZXXJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX7YZ5BtUUN3ME2zMlA1QTl{IN88US=>	Mm\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNU-423	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XQWmlEPTB;Mz6yNFMyOyEQvF2=	NXzxSIFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A427	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmLwTWM2OD1\|LkK1Olk6KM7:TR?=	NWDZXHNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CAL-12T	M2TuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml7YTWM2OD1\|LkSwO\|E{KM7:TR?=	NV[zUmFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
LU-99A	NYntU\|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1O1W2lEPTB;Mz60O\|ExPSEQvF2=	NEPTbHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MS-1	NEnhVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGnxcmhKSzVyPUOuOVM1OjlizszN	NGXsN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-LU-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1LJPWlEPTB;Mz63OlI6PSEQvF2=	NEHFWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW837	NIHEbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV;JR\|UxRTNwN{[zN\|Mh\|ryP	MoDQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ES8	M2THNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;MVo5nUUN3ME2zMlg{QDd5IN88US=>	NVHNbI1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MZ2-MEL	NFW0ZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYHJR\|UxRTNwOUKwPFYh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TGW	M1vkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4D4O2lEPTB;ND6wNVMyOSEQvF2=	NWrCSI5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
GP5d	M3nXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;3cpFyUUN3ME20MlA2OzZ{IN88US=>	NWr5bVMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BB49-HNC	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY\JR\|UxRTRwMUWyNVMh\|ryP	NGTlXXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB13	NH3CcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFvqbldKSzVyPUSuNlY5QDdizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXHMcWI5UUN3ME20MlI5PjF3IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1648	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M37kOmlEPTB;ND6yPVgyQSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LCLC-103H	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLONJRKSzVyPUSuN\|IyQTVizszN	NGjEeFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LS-411N	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3\EOmlEPTB;ND60OFg5PSEQvF2=	Ml7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1092	NXfxcWJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUi3R4E{UUN3ME20MlQ2Pjh5IN88US=>	NXHMNXV7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PANC-10-05	NGnrXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4rXUWlEPTB;ND62PVg1KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
DK-MG	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX;zeIc3UUN3ME20MlgxQTN\|IN88US=>	MoHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
OVCAR-5	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIjoRmJKSzVyPUSuPFEzOjZizszN	M3zLT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CAL-39	NYG0OJlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWTBO5h{UUN3ME20Mlg4PjdizszN	NG[5eIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
TE-441-T	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXfJR\|UxRTRwOUC1N\|ch\|ryP	NXe3NZpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MOLT-16	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGDx[ZdKSzVyPUSuPVUzPTNizszN	MoTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
MCF7	NXTkboFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NE\6UHVKSzVyPUWuNVQ2OTdizszN	NEPwdVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CAPAN-1	NG\jT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmnDTWM2OD13LkK1O\|A4KM7:TR?=	NUHM[otJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PSN1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDpUVRIUUN3ME21MlI4OjN3IN88US=>	MlPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H292	NEfBSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkLTTWM2OD13LkOwNFQ1KM7:TR?=	NInwW3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CPC-N	M33a[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUDJR\|UxRTVwM{m0NVkh\|ryP	NXGzcm9[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
DoTc2-4510	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH6xPJNKSzVyPUWuOFU{PzFizszN	M3LQUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LB1047-RCC	M{e5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXHJR\|UxRTVwNUW5N\|Mh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MHH-ES-1	NV;ucXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1voemlEPTB;NT61PVkxPyEQvF2=	M4D4W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NMC-G1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYD0fZVOUUN3ME21MlcxOjJ5IN88US=>	M2i3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SW1710	NIP1O2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn\XTWM2OD13Lke0O\|UyKM7:TR?=	NETLZlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
YAPC	M3LkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWi1fZA{UUN3ME21Mlc3OjBzIN88US=>	Mn22QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
22RV1	NH3NWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3r4emlEPTB;NT64NFAyQSEQvF2=	M4XwWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-679	M{PpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXnJR\|UxRTVwOEi5OFgh\|ryP	M2\relxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
TCCSUP	M3jxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{X5OmlEPTB;NT65N\|I2QSEQvF2=	M{XidFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
C2BBe1	M2PqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVnJR\|UxRTVwOUO5O{DPxE1?	Mn2xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
TE-15	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4LaeGlEPTB;Nj6wOlYxPSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SCLC-21H	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2e3dmlEPTB;Nj6xNFg1OyEQvF2=	M3rQdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EoL-1-cell	M164V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYS2SJFEUUN3ME22MlE3PTZ\|IN88US=>	M3TMcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NKM-1	NH62bJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGnwSIpKSzVyPU[uNVY4OSEQvF2=	Mke1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1304	MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4GyVGlEPTB;Nj6yO\|QzQCEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NB6	M171RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3;JXmlEPTB;Nj6yPVYzOiEQvF2=	Mk\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NALM-6	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYfJR\|UxRTZwM{OyN{DPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H522	NEe1PJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlTqTWM2OD14LkOzN\|A3KM7:TR?=	NI\ENHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MV-4-11	M1vQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFXTSW5KSzVyPU[uN\|cxPzlizszN	NF\adJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LB2241-RCC	M4e3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml\1TWM2OD14LkO4OlY4KM7:TR?=	Mm\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1417	M4Xkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXLJR\|UxRTZwNEC4OFch\|ryP	NEOwepo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HT-1197	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3LLWGlEPTB;Nj61O\|EzOiEQvF2=	NHP3SI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
P30-OHK	NHL1cZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4\lV2lEPTB;Nj62Nlc4KM7:TR?=	MmjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
ALL-PO	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH3abW9KSzVyPU[uO\|E6OTZizszN	NGDncYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OVCAR-4	NXTLbJY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkmzTWM2OD14Lke1OFA2KM7:TR?=	M3;aS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HCC2157	M{Dwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3fkRWlEPTB;Nj63O\|Q4PSEQvF2=	M1z0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H838	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlmzTWM2OD14Lkm2OFkh\|ryP	NF[4N2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1299	NVjOOINNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUDJR\|UxRTZwOUewPUDPxE1?	NEHyUZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW954	NVTLNm1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTdwMkCwOlgh\|ryP	M2jhUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H441	NEnu[\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfpfGhLUUN3ME23MlM1ODZ3IN88US=>	MmTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-MEL-2	M3vSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUKyXYZmUUN3ME23MlQ5Ozd\|IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KARPAS-45	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU\JR\|UxRTdwNkW5Nlkh\|ryP	M2nCOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CAL-54	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEfhfFJKSzVyPUeuPFI6PzdizszN	M372Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
KYSE-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2n4NmlEPTB;Nz64PFk1OSEQvF2=	NHzmRWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H187	M2T4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLNVnV2UUN3ME23Mlk2QTR5IN88US=>	NUL0bGpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
RT-112	Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zkZ2lEPTB;OD6wPVY4PyEQvF2=	Ml:0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H1437	NWfpZm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1nrTmlEPTB;OD6wPVc6PSEQvF2=	NGK4bYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SNU-449	NIPxclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4DUU2lEPTB;OD6yPFI4OiEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HCC1187	M3r3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnvxTWM2OD16LkK5N\|kyKM7:TR?=	NY\2dG1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2030	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXnJR\|UxRThwM{e3NVQh\|ryP	NHO1VGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HuO-3N1	M3XLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWTJR\|UxRThwM{e4OFQh\|ryP	NH;Me4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-792	NInjZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlPhTWM2OD16LkSxOVI4KM7:TR?=	M2L6blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MIA-PaCa-2	M17Ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXq5b3VFUUN3ME24Mlg2PTB6IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-N-FI	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYHJR\|UxRTlwMESyOUDPxE1?	M2HsT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MMAC-SF	NGTZe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILWW3BKSzVyPUmuNFk4PTFizszN	M2rQSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H28	NILBTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{frRmlEPTB;OT6xNFQ3QSEQvF2=	NU\LOYVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
ETK-1	NYrKfXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYDHVIlRUUN3ME25MlI6QTd2IN88US=>	NGXOTmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1993	NF7zOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUfJR\|UxRTlwNESyOlEh\|ryP	M{LRZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
no-11	NXrkV4tQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXP4dZVyUUN3ME25MlQ4OTJizszN	NFzJPGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
ChaGo-K-1	NIK2fllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFfrVZdKSzVyPUmuOVE2QDNizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCCIT	NVPyRo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlzMTWM2OD17LkWzNVY6KM7:TR?=	NYDJW21vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SAS	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4r1RmlEPTB;MUCuNlQ5KM7:TR?=	MoPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
A673	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnNblZKSzVyPUGwMlM4ODRizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1522	NHzGTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkjxTWM2OD1zMD6zO\|A4KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H810	Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF;rOFZKSzVyPUGwMlM6ODdizszN	MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
IST-MES1	NVfL[ZV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUPJR\|UxRTFyLkS1OlQh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GR-ST	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGXRbHhKSzVyPUGwMlUxOjRizszN	NFjmTWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SUP-T1	NIH5S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2LDTGlEPTB;MUCuO\|MyPyEQvF2=	NFqwSpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NB5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUOyZ3dKUUN3ME2xNE46ODJ{IN88US=>	NU\VRZJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MZ1-PC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2TWNmlEPTB;MUCuPVU4OSEQvF2=	NIm5[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SK-CO-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2nWcWlEPTB;MUCuPVk{OSEQvF2=	MlfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
Capan-2	M{PQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUDJR\|UxRTFzLkOxPVgh\|ryP	MnvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
697	NGfjZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX3JR\|UxRTFzLk[3OVch\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
REH	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkKyTWM2OD1zMT63OFUyKM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
GI-1	NVz6W4hJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXPmWnB4UUN3ME2xNU45PjF3IN88US=>	MonoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
BB65-RCC	NV7SR2k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1n3OmlEPTB;MUKuNFkyPiEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1651	M4TMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LIbGlEPTB;MUKuNlQ4QCEQvF2=	NVu0OnBHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1618	NHP6NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NILXfZVKSzVyPUGyMlM6PzZizszN	M{C5dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2081	M{XRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWTXU5h3UUN3ME2xNk43OTRzIN88US=>	M1riPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GCIY	M2nISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3jUWRKSzVyPUGyMlczOTNizszN	NXjlRYQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NY	NGLtTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVXJR\|UxRTF\|LkC2OFMh\|ryP	Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
PANC-03-27	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGPJOnpKSzVyPUGzMlA5ODdizszN	NXHuOGU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BHY	M1PHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXLDTmtSUUN3ME2xN{4zOTJzIN88US=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-OV-3	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NG\LUlNKSzVyPUGzMlM4PjNizszN	MljFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
5637	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml[xTWM2OD1zMz63O\|U6KM7:TR?=	NHz5Xms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LC-1F	MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2\QUmlEPTB;MUSuNFM2PiEQvF2=	MnXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNB75	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIXPO5JKSzVyPUG0MlA{QDNizszN	MmnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CHP-212	NUnqZXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{T3OmlEPTB;MUSuNFQ3PCEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HT-1376	M1XkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVnJR\|UxRTF2LkGxNlYh\|ryP	NIfOXIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MONO-MAC-6	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVTwcWM{UUN3ME2xOE4yPTB{IN88US=>	M4fPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
CA46	NIi4N4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYPkRnZyUUN3ME2xOE4yQDJ5IN88US=>	NXzad3liRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SCC-15	M{j6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk[zTWM2OD1zND61OVg{KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ATN-1	NEC1OYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3rwcWlEPTB;MUSuOlYzPyEQvF2=	NH21WVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2405	NXPGTZBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV7xdoZ1UUN3ME2xOE45OTV5IN88US=>	NFe0N2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H716	NWHxXZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M17OU2lEPTB;MUSuPFQ6OyEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SW620	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV\ONFRVUUN3ME2xOE46ODF2IN88US=>	NHjaZ2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H226	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkDuTWM2OD1zND65NFg2KM7:TR?=	MlznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW962	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUDJR\|UxRTF2Lkm0N\|Ih\|ryP	MlHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KYSE-150	NVfYfWV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHxTWM2OD1zND65OVUh\|ryP	NIjJenI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OCUB-M	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{DafWlEPTB;MUSuPVg5OyEQvF2=	M4G0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ES7	NWPLbXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXjJR\|UxRTF3LkC5PFQh\|ryP	NWXPcHB{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SW1463	NUm3OlB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlnDTWM2OD1zNT60NlI{KM7:TR?=	MonvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CAKI-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3u1OGlEPTB;MUWuOVM1PiEQvF2=	NH3nfYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MKN28	M2PNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LRZmlEPTB;MUWuOVQ4QSEQvF2=	M17zRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SW13	NVjheIhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MojOTWM2OD1zNT62NVgh\|ryP	NUP0bpFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
A3-KAW	M1rG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWLhb\|ZvUUN3ME2xOU46Pjl5IN88US=>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LU-65	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlnKTWM2OD1zNT65O\|Y5KM7:TR?=	MkLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
Calu-1	MmPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2XjfmlEPTB;MU[uNFM3QCEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
ST486	MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUTJR\|UxRTF4LkC0N\|Eh\|ryP	NEXmXYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BB30-HNC	NHnHfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1TBSWlEPTB;MU[uNVI1PiEQvF2=	NUTVZ4dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
EGI-1	NHvXZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mm\3TWM2OD1zNj60OFYh\|ryP	M4j2XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
SH-4	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXPi[Y5lUUN3ME2xOk41PzNzIN88US=>	NUPPcFNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
MN-60	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGPpeHJKSzVyPUG3MlIzQTdizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MPP-89	M3ryU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXzJR\|UxRTF5LkK0OVkh\|ryP	M3TZUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A2780	M1LzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn3wTWM2OD1zNz60NVM6KM7:TR?=	MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
Daoy	Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlnNTWM2OD1zNz60Olk2KM7:TR?=	M3TqUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2126	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXOxWGpDUUN3ME2xO{41PzdzIN88US=>	NX7wUHBERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1563	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVTCT3VKUUN3ME2xO{41QTF5IN88US=>	NHn6SIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
8-MG-BA	NYPaOlRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUPJR\|UxRTF5Lk[2OFgh\|ryP	NWPWNHFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
786-0	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnyxTWM2OD1zNz64N\|U{KM7:TR?=	MnTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
AM-38	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3yyW2lEPTB;MUeuPVMxPiEQvF2=	MnzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
COLO-824	NIXGWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYrmRoI6UUN3ME2xPE41PDN4IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SK-MEL-30	Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUC0[3d[UUN3ME2xPE42ODh{IN88US=>	NI\YXFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
CESS	NXHLe4Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV7uXINTUUN3ME2xPE44PjB7IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BL-70	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmXQTWM2OD1zOD64NVU3KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2170	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmf1TWM2OD1zOD65NVc6KM7:TR?=	NYT1NFYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HT-3	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYLJR\|UxRTF6Lkm4N{DPxE1?	M1nKWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
BOKU	MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml[yTWM2OD1zOT6wN\|gyKM7:TR?=	NGH3dY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HPAF-II	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXq0bJVsUUN3ME2xPU4{ODF3IN88US=>	MnfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
KGN	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NInPbpFKSzVyPUG5MlQ4PjVizszN	M1fkflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MC-CAR	M1fIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoDsTWM2OD1zOT62N\|E{KM7:TR?=	NH\UXZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BHT-101	M1OwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmfSTWM2OD1zOT63O\|ch\|ryP	NEf3VnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1783	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkP0TWM2OD1zOT63PFA3KM7:TR?=	NH\VPVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KP-N-YN	M1nsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoXaTWM2OD1{MD6wNlYzKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LU-165	M3:wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEL2e5RKSzVyPUKwMlU2PzFizszN	NFfuV3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
GOTO	NH;ZcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPITWM2OD1{MD62OFUyKM7:TR?=	M13Yd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
EFM-19	NIW0TGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXjJR\|UxRTJzLkC3NVYh\|ryP	NYHNO4hKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
CTV-1	NYTZO5NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2LmNmlEPTB;MkGuNVA2PCEQvF2=	Mk\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HEL	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoD3TWM2OD1{MT60NlE3KM7:TR?=	NIfibow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SNU-C2B	M1nuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXnJR\|UxRTJzLkSyOkDPxE1?	M17GPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
ECC4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{T2UWlEPTB;MkGuO\|A4KM7:TR?=	M1zWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NEC8	NX;wfotDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFfnPVRKSzVyPUKxMlg{PjhizszN	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KMOE-2	NV7SOVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1PyR2lEPTB;MkGuPFkzOSEQvF2=	MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
NCI-H524	MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH;2bmpKSzVyPUKyMlA5ODhizszN	NEW4N449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
WSU-NHL	NVTXOHJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn\0TWM2OD1{Mj6xOVc4KM7:TR?=	NEPPXYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SF126	M2L0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4qwW2lEPTB;MkKuNlQ3QSEQvF2=	MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HOP-92	M3LReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGnDcWlKSzVyPUKyMlMyPjdizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
CTB-1	NFnmV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXzpWYJzUUN3ME2yNk41Pjd5IN88US=>	NWTIWWtqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KYSE-270	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUnweYI{UUN3ME2yNk46OzV5IN88US=>	NXe5bXZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-MEL-24	NEPw[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVy3PZVoUUN3ME2yN{4yQDdizszN	NUnScIVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
Calu-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MW\JR\|UxRTJ\|LkKxNlgh\|ryP	M{i3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GAMG	NFroe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{PxcWlEPTB;MkOuNlM3PyEQvF2=	NHXT[YI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SW1573	NXjRV2NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXnJR\|UxRTJ\|Lke0NVUh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3rvZ2lEPTB;MkSuNFE6PCEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
TK10	NWDm[WhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV\JR\|UxRTJ2LkWwNVMh\|ryP	Mn7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LB373-MEL-D	NFPWblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{XxfWlEPTB;MkSuOlA3PCEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
KALS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHGUplpUUN3ME2yOE44OzJ5IN88US=>	M3nBelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HUTU-80	Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXzJR\|UxRTJ3LkiwN\|Ih\|ryP	MmXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HuP-T3	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXnJR\|UxRTJ4LkG2O\|Qh\|ryP	NGXycpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
OE19	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlrmTWM2OD1{Nj6yNVU{KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
J82	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVP3NI5uUUN3ME2yOk4zPDdzIN88US=>	M33ydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
DU-4475	NHjvPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXPJR\|UxRTJ4LkO4NVkh\|ryP	NF\lPGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
DMS-53	NUHtdoFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWjSUFRqUUN3ME2yOk42OTN6IN88US=>	NFzzNW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
COLO-741	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnfVTWM2OD1{Nj64N\|Q1KM7:TR?=	Mmr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW48	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFHRRohKSzVyPUK2Mlg5OiEQvF2=	NVzING86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
IGR-1	NIXve2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlWzTWM2OD1{Nj65N\|M1KM7:TR?=	Mn;oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
639-V	NVS5SIxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXzJR\|UxRTJ5LkCyOFUh\|ryP	NES4eXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LK-2	M1HI[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUHsNnFIUUN3ME2yO{41OTRzIN88US=>	NFq0U2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H2347	NGiz[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVjCe5dkUUN3ME2yO{46Pjl7IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H2228	NXP4OHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDETWM2OD1{OD6wPVA2KM7:TR?=	MmToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LS-123	NFLPVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV7EdWU3UUN3ME2yPE4yOjZ{IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
U031	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3Hpc2lEPTB;MkiuNlUzKM7:TR?=	NVO2PWw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1792	NWflXod[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NITuWpJKSzVyPUK4MlQ4OjFizszN	NXTTPWFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H2087	NHLJWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWPJR\|UxRTJ6Lke1OVIh\|ryP	M{TPdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2342	NVv5XHFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVHJR\|UxRTJ7LkWyNFgh\|ryP	MkfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW626	NFTwemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHS0RZRKSzVyPUK5Mlc2PiEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUTJR\|UxRTJ7LkixOUDPxE1?	M1u4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
RXF393	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGfYdFVKSzVyPUOwMlA6PTJizszN	MoDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
LC4-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2L0T2lEPTB;M{CuN\|A6OiEQvF2=	NULOeoZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H1694	NVPBbWFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlXSTWM2OD1\|MD62OlI1KM7:TR?=	NYC0[VJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
K5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmCyTWM2OD1\|MD65O\|AzKM7:TR?=	M2r5cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HDLM-2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVzodnpOUUN3ME2zNE46PzJ3IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
BCPAP	NX3FcI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVzVUFJwUUN3ME2zNU45Ozd7IN88US=>	NIHmUHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BC-3	M2jSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVzJR\|UxRTN{LkG0NFMh\|ryP	M1XkZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LB996-RCC	M4nHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVnJR\|UxRTN{LkKzOVgh\|ryP	M1zSb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
NCI-H2009	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2LtNGlEPTB;M{KuOFk5OSEQvF2=	NXzVfVdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
HTC-C3	NGjJPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX7JR\|UxRTN\|Lke1NVkh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
LAMA-84	NIf3e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGPad\|JKSzVyPUO0MlQ1ODdizszN	Ml75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
CCRF-CEM	MlPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH\YTmtKSzVyPUO0MlU4OTVizszN	NXPFeVk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
AN3-CA	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml7oTWM2OD1\|NT6wOVY5KM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
NCI-H1734	NEL0XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlXITWM2OD1\|NT6yOVYyKM7:TR?=	NIH5Zpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
Ca-Ski	NV:4bYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEWyWVFKSzVyPUO1MlQyODFizszN	MkPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
U-266	M1rkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4j5OGlEPTB;M{WuOlEyPCEQvF2=	NFzWRZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
SBC-5	M1L5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NELpN\|BKSzVyPUO1Mlc4QDFizszN	M1PudFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
GT3TKB	NYrxUW9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3oTWM2OD1\|Nz6xNVUh\|ryP	M33jblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
MDA-MB-175-VII	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXjIfplOUUN3ME2zO{4zOjR6IN88US=>	NVjoNGd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
PFSK-1	NFrCN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFHzc2hKSzVyPUO3MlI1OzVizszN	M{XPNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
IMR-5	NVnlZ2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWXJR\|UxRTN5LkK0PFch\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
Daudi	M1\iTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MULJR\|UxRTN5LkO1PVch\|ryP	NG\iWYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
A498	MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUPXe4xPUUN3ME2zO{44OjF6IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
SCC-4	M1\Qd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{Ppb2lEPTB;M{euO\|g1OyEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COLO-680N	MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX3XNZByUUN3ME2zPE4zQDh3IN88US=>	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SK-MES-1	M2fSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml7KTWM2OD1\|OD6zNlE2KM7:TR?=	Mn3jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SR	NWr2NJl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWe5ZpJxUUN3ME2zPE42PDl3IN88US=>	NEG2dG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	NUHJPWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWfoT4d5UUN3ME2zPE42PjN5IN88US=>	NWHBe\|JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
SK-HEP-1	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX\JR\|UxRTN6Lke4NlIh\|ryP	NFTqOZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
BPH-1	NEW2dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHrIfHNKSzVyPUO4Mlg{OjlizszN	NFq1OI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
NCI-H1755	M1\yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVLYfFlPUUN3ME2zPU42QDF5IN88US=>	M1[yTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
LXF-289	Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2ThWGlEPTB;M{muPFA5PCEQvF2=	MnTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SW1088	M{[3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF3JNG9KSzVyPUSwMlIyODdizszN	NEnFPY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
MOLT-4	NGTQT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIriNndKSzVyPUSwMlI6ODFizszN	NGfmd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
AsPC-1	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFj4RmVKSzVyPUSwMlQ2QDNizszN	NIrNcW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
HOP-62	M13hemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWfm[WN1UUN3ME20NE43PTZ6IN88US=>	M{[4T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
A172	MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFXOXppKSzVyPUSwMlg2OTFizszN	Ml[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SN12C	NXvzXFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFewd3dKSzVyPUSwMlk{QDVizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
MDA-MB-231	M1XN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1PKOGlEPTB;NECuPVg6QCEQvF2=	M{G4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
RPMI-2650	M1nVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfrPFJHUUN3ME20NU4yPTl\|IN88US=>	NGfpWok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
KYSE-140	NHPHWpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2WzTWlEPTB;NEGuPFEzOyEQvF2=	M1vaZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
KINGS-1	M1HXdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoPMTWM2OD12Mj60Olk4KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
HSC-3	NXKxNmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlzsTWM2OD12Mj62OlYyKM7:TR?=	M{W1dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
PC-14	MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEXhUmpKSzVyPUSzMlE5QDJizszN	M{DH[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COR-L105	M3jSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXHGPHZZUUN3ME20N{43PTB{IN88US=>	NVLybJhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
BE-13	NHPGSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX\JR\|UxRTR2LkKzO\|Eh\|ryP	NXP3VmlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
NCI-H661	MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmnnTWM2OD12ND6yPVU5KM7:TR?=	NGLRTYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODlzNkS0M{c,W0GQR1XSQE9iRg>?
IST-MEL1	M4Xqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXvJc3Q3UUN3ME20OE4{PTl7IN88US=>	M{TwclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
HCC1806	MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{X5[WlEPTB;NESuOVg4OyEQvF2=	M1WxOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
COLO-800	NUPSOIpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn\VTWM2OD12ND64OFU{KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
IST-SL2	NYrFWZhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3W0SmlEPTB;NEWuNVI1PyEQvF2=	M2\ZVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
8305C	MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1r3cWlEPTB;NEWuN\|A6KM7:TR?=	M2fIe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExQTF4NESvK\|5USU6JRWK8M4E,
UACC-62	M2DYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY[yelZiUUN3ME20Ok4zQDd3IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
COR-L23	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\GRWNKSzVyPUS3MlE6QSEQvF2=	MnTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
EFE-184	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWXnW2RuUUN3ME20O{4{QDhizszN	MmHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
DMS-114	M3fIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH3ifHlKSzVyPUS3MlQyPDlizszN	NYrJ[YpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB7MU[0OE8oRlODTlfFVlww[T5?
KYSE-520	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{TlWGlEPTB;NEiuOVMyPSEQvF2=	MoWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
SNG-M	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXfJR\|UxRTR7LkSzOEDPxE1?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFkyPjR2Lze+V2FPT0WUPD;hQi=>
A2058	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHNfFB7UUN3ME20PU41QDh3IN88US=>	MmjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA6OTZ2ND:nQnNCVkeHUkyvZV4>
HEK293	NY[yPIhLTnWwY4Tpc44h[XO\|YYm=	M4LXSVYxKG2rboO=	NUDwTY9OUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBKT0ZvMTDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHH1eI9xcG:\|cHjvdplt[XSrb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNiZn;scI94\WRiYomgTWdHNTFic4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDxeYFvfGm2YYTpeoUhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|LDDJR\|UxKD1iMD6wNFI5KM7:TT6=	M1PpR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUWxO\|U{Lz5{Nkm1NVc2OzxxYU6=
Ba/F3	MXrGeY5kfGmxbjDhd5NigQ>?		NIfSSGNKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJGlITi1zIILlZ4VxfG:{IDj1cotvd3ewIH;ybYdqdilidILhcpNn\WO2ZXSgbY4hSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyIE2gNE4xODd4IN88UU4>	MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUG3OVMoRjJ4OUWxO\|U{RC:jPh?=
HEK293	M4DVZmZ2dmO2aX;uJIF{e2G7	MkjGOlAhdWmwcx?=	NYHjT4ZKUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBqdnO3bHnuJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emGwc3\lZ5Rm\CCrbjDISWszQTNiY3XscJMheHKndILlZZRm\CCob4KgOlAhdWmwczDmc4xtd3enZDDifUBKT0ZvMTDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjCxNEBucW6\|IHL5JJF2[W62aYTheIl3\SCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTCwMlAyPiEQvF2u	MmLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NUG3OVMoRjJ4OUWxO\|U{RC:jPh?=
A431	MWnGeY5kfGmxbjDhd5NigQ>?		NHSxc4lKdmirYnn0bY9vKG:oIFnHSlFTKGmwdILhZ4VtdHWuYYKgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFG0N\|Eh[2WubIOgZpkhTUyLU1GsJGlEPTBiPTCwMlAyQCEQvF2u	NYj6elE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFY3PTVpPkKwN\|Q3PjV3PD;hQi=>
3T3	MV7GeY5kfGmxbjDhd5NigQ>?		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGlITjGUIHX4dJJme3OnZDDpckBud3W\|ZTCzWFMh[2WubIOgZpkhTUyLU1GgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjB{NDFOwG0v	NVf2fIJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyOVE5OjRpPkKxNlUyQDJ2PD;hQi=>
NIH 3T3	Ml\rSpVv[3Srb36gZZN{[Xl?	NIfYWXAzKGi{cx?=	MlfyTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDoeY1idiCLR1[tNXIhd3[ncnX4dJJme3OnZDDpckBud3W\|ZTDOTWghO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IFnHSlEucW6mdXPl[EBxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDJiaILzJJBzcW:{IITvJGlITjFiaX7keYN1cW:wIH3lZZN2emWmIHHmeIVzKDF3IH3pcpMh[nliRVzJV2EtKEmFNUCgQUAxNjB{NDFOwG0v	NYrKXotoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4OjFpPkK0PVAxPzJzPD;hQi=>
Ba/F3	MV\GeY5kfGmxbjDhd5NigQ>?		NHPBdIxKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIlve3WuaX6gdoVk\XC2b4KgLJVvc26xd36gc5Jq\2mwKTD0doFve2[nY4Tl[EBqdiCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUCgQUAxNjF{NjFOwG0v	M1vsfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUWxO\|U{Lz5{Nkm1NVc2OzxxYU6=
A673	MVTxTHRUKGG\|c3H5		MknidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	NF;UWIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NUfl[ZlYeUiWUzDhd5NigQ>?		NFjJbVZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NFnad3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MmnzdWhVWyCjc4PhfS=>		NXf5dIx{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NE\pWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NXnPfnUzeUiWUzDhd5NigQ>?		MnvpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	M{C5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	M{H3N5FJXFNiYYPzZZk>		MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NIHQfm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MkjIdWhVWyCjc4PhfS=>		MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	NXnROnJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MWfxTHRUKGG\|c3H5		NXjaTGtteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NYTsWHBNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	Mn;0dWhVWyCjc4PhfS=>		M2LkUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	M1;ySlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MYrxTHRUKGG\|c3H5		MnXTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	M1:1OpFJXFNiYYPzZZk>		M3i5UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NUPlVYpHeUiWUzDhd5NigQ>?		NYfWW\|JDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	M1HwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MVrxTHRUKGG\|c3H5		NYe3bWR[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NG\DcnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; PubMed: 26052929 Mol Carcinog Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells. p-IGF1R / IGF1R / p-mTOR / mTOR ; PubMed: 28440057 Cancer Med Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot. cleaved caspase-3 / cleaved PARP; PubMed: 28440057 Cancer Med Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control. pSrc(Y416) / Src; PubMed: 26515601 Oncotarget A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis. p-STAT3(Y705) / STAT3 ; PubMed: 26041671 Mol Cancer H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days. pS6 / S6; PubMed: 21257723 Clin Cancer Res Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.	26052929 28440057 26515601 26041671 21257723
Immunofluorescence	FoxO1; PubMed: 27535223 J Biol Chem After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min. A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.	27535223
Growth inhibition assay	Cell viability; PubMed: 26136493 Neuro Oncol InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.	26136493

In vivo

OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the V_max is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. ^[1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Protein kinase biochemical assays: Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log₁₀ compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerPro^TM Kinase Selectivity Assay Kit.
Cell Research:^[1]	- Collapse Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells Concentrations: 0.02-0.8 μM Incubation Time: 3 days Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model Dosages: 25 mg / kg and 75 mg / kg Administration: Orally administrated at once-daily oral dose for 14 days (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	84 mg/mL (199.29 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Linsitinib (OSI-906) SDF

Molecular Weight	421.49
Formula	C₂₆H₂₃N₅O
CAS No.	867160-71-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CC(C1)C2=NC(=C3N2C=CN=C3N)C4=CC5=C(C=C4)C=CC(=N5)C6=CC=CC=C6)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02546544	Completed	Drug: Linsitinib	Relapsed Ewing Sarcoma\|Refractory Ewing Sarcoma	University of Oxford\|European Organisation for Research and Treatment of Cancer - EORTC\|European Commission\|Astellas Pharma Inc\|Oxford University Hospitals NHS Trust	March 2014	Phase 2
NCT01672736	Terminated	Drug: ASP7487 Velcade Dexamethasone	Multiple Myeloma	University Health Network Toronto\|Multiple Myeloma Research Consortium\|Astellas Pharma Inc	September 2012	Phase 1\|Phase 2
NCT01529684	Completed	Drug: radio-labeled OSI-906\|Drug: OSI-906	Advanced Solid Tumors\|Pharmacokinetics of 14C-OSI-906	Astellas Pharma Global Development Inc.\|Astellas Pharma Inc	March 19 2012	Phase 1
NCT01221077	Completed	Drug: OSI-906\|Drug: Erlotinib\|Drug: Placebo	NSCLC\|Non Small Cell Lung Cancer	Astellas Pharma Inc	April 8 2011	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?
Answer:
OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Pan IGF-1R Inhibitor

GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.
Most Potent IGF-1R Inhibitor

BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.
IGF-1R Inhibitor in Clinical Trial

BMS-754807 : Phase II for Breast Cancer.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Related IGF-1R Products

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP, AXL1717) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R). Picropodophyllin (PPP) induces apoptosis with antineoplastic activity.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 (CS-0117) is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 (GSK 552602A) is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
GSK1904529A

GSK1904529A (GSK 4529) is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
BMS-754807

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Features:Muti-inhibitor of the IGR-1R/IR family.
AG-1024

AG-1024 (Tyrphostin, AGS 200) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

Linsitinib (OSI-906)